Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose pharmacokinetics and glucodynamics of insulin peglispro in healthy Japanese males
jRCT2080222319Phase 1
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2013
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, single-arm trial of insulin peglispro in diabetes mellitus (DM), sponsored by Eli Lilly and Company. Primary endpoints: Pharmacokinetics of insulin peglispro and Glucodynamic effects of insulin peglispro.
02
Drugs
insulin peglispro
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on jRCT2080222319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222319.